Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA.

MLA

Heidrich, Benjamin, et al. “Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA.” PloS One, vol. 9, no. 10, Oct. 2014, p. e108751. EBSCOhost, https://doi.org/10.1371/journal.pone.0108751.

APA

Heidrich, B., Wiegand, S. B., Buggisch, P., Hinrichsen, H., Link, R., Möller, B., Böker, K. H. W., Teuber, G., Klinker, H., Zehnter, E., Naumann, U., Busch, H. W., Maasoumy, B., Baum, U., Hardtke, S., Manns, M. P., Wedemeyer, H., Petersen, J., & Cornberg, M. (2014). Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA. PloS One, 9(10), e108751. https://doi.org/10.1371/journal.pone.0108751

Chicago

Heidrich, Benjamin, Steffen B Wiegand, Peter Buggisch, Holger Hinrichsen, Ralph Link, Bernd Möller, Klaus H W Böker, et al. 2014. “Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA.” PloS One 9 (10): e108751. doi:10.1371/journal.pone.0108751.